
Merck & Co. MRK
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.5 B |
Market Cap[1] |
$ 340 B |
EBITDA (LTM) |
$ 2.77 B |
P/E (LTM) |
70.65 |
P/S (LTM) |
4.88 |
EPS (LTM) |
1.82 |
Merck & Co., Inc. is a global pharmaceutical company that specializes in the development, manufacturing, and distribution of innovative medicines, vaccines, and animal health products. Founded in 1891, Merck has grown to become one of the largest pharmaceutical companies in the world, with operations in over 140 countries.
The company's mission is to improve the health and well-being of people and animals around the world. Merck is committed to discovering new treatments and cures for some of the most challenging diseases, including cancer, Alzheimer's disease, and HIV/AIDS. The company has a strong pipeline of products in development, with a focus on immunotherapy and oncology.
Merck is also a leader in the development and distribution of vaccines. The company has played a key role in the fight against infectious diseases such as measles, mumps, rubella, and HPV. Merck's vaccines have saved countless lives around the world and continue to be an important tool in preventing disease outbreaks.
In addition to its pharmaceutical and vaccine business, Merck also has a thriving animal health division. The company develops and manufactures products for livestock, pets, and wildlife. Merck's animal health products are used to prevent and treat diseases in animals, improving their health and welfare.
Merck is committed to operating responsibly and sustainably. The company has set ambitious goals to reduce its environmental impact, improve the health and safety of its employees, and support the communities where it operates. Merck has been recognized for its sustainability efforts, including being named to the Dow Jones Sustainability Index for the past 16 years.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | ||
|
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market | ||
|
Qilian International Holding Group Limited
QLI
|
- | -6.08 % | $ 184 M | Nasdaq Global Select Market | ||
|
Happiness Biotech Group Limited
HAPP
|
- | 1.35 % | $ 17.8 M | Nasdaq Capital Market | ||
|
Synthetic Biologics
SYN
|
- | 1.32 % | $ 16.2 M | NYSE American | ||
|
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | ||
|
BioXcel Therapeutics
BTAI
|
$ 1.19 | 5.31 % | $ 14.5 M | Nasdaq Global Select Market,SPB | ||
|
Burford Capital Limited
BUR
|
$ 4.37 | 0.23 % | $ 958 M | NYSE | ||
|
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | ||
|
BeyondSpring
BYSI
|
$ 0.84 | 34.27 % | $ 34.5 M | Nasdaq Capital Market | ||
|
Corner Growth Acquisition Corp.
COOL
|
- | -0.89 % | $ 114 M | Nasdaq Global Select Market | ||
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Cerus Corporation
CERS
|
$ 2.98 | 4.93 % | $ 568 M | Nasdaq Global Market | ||
|
Compugen Ltd.
CGEN
|
$ 2.41 | 4.17 % | $ 225 M | Nasdaq Global Market,SPB | ||
|
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | ||
|
Abcam plc
ABCM
|
- | - | $ 4.9 B | Nasdaq Global Select Market | ||
|
Завод ДИОД
DIOD
|
- | - | - | MOEX,SPB | ||
|
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Hepion Pharmaceuticals
HEPA
|
- | -18.79 % | $ 39.3 K | Nasdaq Capital Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Champions Oncology
CSBR
|
$ 5.1 | 2.63 % | $ 70.5 M | Nasdaq Capital Market | ||
|
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | ||
|
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | Nasdaq Global Market | ||
|
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market | ||
|
Adial Pharmaceuticals
ADIL
|
$ 3.98 | 1.86 % | $ 2.66 M | Nasdaq Capital Market | ||
|
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | ||
|
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | ||
|
AnaptysBio
ANAB
|
$ 58.47 | 4.37 % | $ 1.68 B | Nasdaq Global Select Market,SPB | ||
|
Anika Therapeutics
ANIK
|
$ 21.5 | 1.56 % | $ 308 M | Nasdaq Global Select Market,SPB | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | ||
|
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | ||
|
Aurinia Pharmaceuticals
AUPH
|
$ 15.47 | 1.91 % | $ 2.08 B | Nasdaq Global Market | ||
|
GlycoMimetics
GLYC
|
- | 9357.83 % | $ 1.01 B | Nasdaq Global Market | ||
|
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Bicycle Therapeutics plc
BCYC
|
$ 3.9 | 0.24 % | $ 270 M | Nasdaq Global Select Market | ||
|
Beam Therapeutics
BEAM
|
$ 26.75 | 0.91 % | $ 2.65 B | Nasdaq Global Select Market | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
BioMarin Pharmaceutical
BMRN
|
$ 67.36 | 0.99 % | $ 12.9 B | Nasdaq Global Select Market,SPB | ||
|
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.